Biohaven Seeks $150 Million From Wall Street Following FDA Rejection

The FDA rejection of Biohaven's troriluzole for spinocerebellar ataxia signifies a regulatory setback, leading to significant financial implications, budget cuts, and a shift in focus to other pipeline candidates. This event highlights the challenges in gaining FDA approval and the importance of diversifying drug portfolios in the biotech/pharma industry.